Recent advances in haemostasis and thrombosis

Retina

Volumn 29, Issue 1, 2009, Pages 1-7

  Vine, Andrew K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7A; PROTEINASE ACTIVATED RECEPTOR; THROMBIN; THROMBOPLASTIN; BLOOD CLOTTING FACTOR 5 LEIDEN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL ADHESION; HEMOSTASIS; IN VIVO STUDY; INFLAMMATION; THROMBOPHILIA; VEIN THROMBOSIS; BLOOD; EYE DISEASE; HUMAN; OPHTHALMOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOSIS;

EYE DISEASES; FACTOR V; HEMOSTASIS; HUMANS; INFLAMMATION; OPHTHALMOLOGY; THROMBOSIS;

EID: 61549116208     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31819091dc     Document Type: Article

References (39)

1. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Hae-most 2007;98:530-542.
2. Dahlback B. Blood coagulation. Lancet 2000;355:1627-1632.
3. Virchow R. Phlogose und thrombose im GefaBsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt: Verlag von Meidinger Sohn Comp. 1856.
4. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
5. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964;202:498-499.
6. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003;10: 797-811.
7. Seligsohn U. Factor XI in heamostasis and thrombosis: past, present, and future. Thromb Haemost 2007;98:84-89.
8. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74:5260-5264.
9. Gailani D, Broze GJ. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993;19:396-404.
10. Hoffman M, Monroe DM III. A cell-based model of hemosta-sis. Thromb Haemost 2001;85:958-965.
11. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterio-scler Thromb Vasc Biol 2007;27:1687-1693.
12. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177:4794-4802.
13. Ardoin SP, Shanahan JC, Pisetsky DS. The role of micropar-ticles in inflammation and thrombosis. Scand J Immunol 2007; 66:159-165.
14. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 1979;279:636-638.
15. Renne T, Gailani D. Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 2007;5:733-741.
16. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-281.
17. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002;87:774-776.
18. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696- 701.
19. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006;108:4045-4051.
20. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006;126:411-415.
21. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003;1:658-661.
22. Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency - a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999;82:1240-1246.
23. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008;28: 233-242.
24. Griffin JH, Fernandez JA, Mosnier LO, et al. The promise of protein C. Blood Cells Mol Dis 2006;36:211-216.
25. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29:S48-S51.
26. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699 -709.
27. Dahlback B. The tale of protein S and C4b-binding protein, a story of affection. Thromb Haemost 2007;98:90-96.
28. Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007;7:855-870.
29. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006;114:1070-1077.
30. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothe-lium. Arterioscler Thromb Vasc Biol 2004;24:41-53.
31. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84: 579-621.
32. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrom-binase complex. J Biol Chem 1980;255:274-283.
33. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
34. Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999;93:2552-2558.
35. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
36. The Eye Disease Case-control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116: 286-296.
37. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114: 545-554.
38. Frosst P, Bloom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methyl-enetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
39. Vine AK, Samma SM. Prothrombotic states in retinal artery and vein occlusions. Semin Cerebrovasc Dis Stroke 2002;2: 134-142.